Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$72.62
+0.9%
$65.64
$29.95
$118.84
$3.09B3.22512,391 shs413,760 shs
Illumina, Inc. stock logo
ILMN
Illumina
$186.65
-1.9%
$166.44
$88.00
$196.66
$28.78B1.471.81 million shs1.25 million shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.44
-3.4%
$1.43
$1.09
$2.73
$462.80M2.295.58 million shs7.07 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$41.19
-0.8%
$37.34
$32.53
$57.81
$8.55B0.643.06 million shs2.22 million shs
10x Genomics stock logo
TXG
10x Genomics
$43.74
-1.7%
$32.16
$11.16
$46.32
$5.65B2.053.18 million shs2.57 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+0.92%+0.86%+22.15%+40.44%+98.36%
Illumina, Inc. stock logo
ILMN
Illumina
-1.89%-1.87%+17.32%+38.77%+92.50%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-3.36%-7.69%+7.46%-14.79%-3.36%
Qiagen N.V. stock logo
QGEN
Qiagen
-0.78%-0.81%+12.36%-0.12%-19.02%
10x Genomics stock logo
TXG
10x Genomics
-1.66%+2.36%+36.13%+67.71%+253.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$72.62
+0.9%
$65.64
$29.95
$118.84
$3.09B3.22512,391 shs413,760 shs
Illumina, Inc. stock logo
ILMN
Illumina
$186.65
-1.9%
$166.44
$88.00
$196.66
$28.78B1.471.81 million shs1.25 million shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.44
-3.4%
$1.43
$1.09
$2.73
$462.80M2.295.58 million shs7.07 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$41.19
-0.8%
$37.34
$32.53
$57.81
$8.55B0.643.06 million shs2.22 million shs
10x Genomics stock logo
TXG
10x Genomics
$43.74
-1.7%
$32.16
$11.16
$46.32
$5.65B2.053.18 million shs2.57 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+0.92%+0.86%+22.15%+40.44%+98.36%
Illumina, Inc. stock logo
ILMN
Illumina
-1.89%-1.87%+17.32%+38.77%+92.50%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-3.36%-7.69%+7.46%-14.79%-3.36%
Qiagen N.V. stock logo
QGEN
Qiagen
-0.78%-0.81%+12.36%-0.12%-19.02%
10x Genomics stock logo
TXG
10x Genomics
-1.66%+2.36%+36.13%+67.71%+253.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRAIL, Inc. stock logo
GRAL
GRAIL
2.30
Hold$67.78-6.67% Downside
Illumina, Inc. stock logo
ILMN
Illumina
2.37
Hold$156.88-15.95% Downside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.80
Reduce$1.8327.31% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.36
Hold$43.345.23% Upside
10x Genomics stock logo
TXG
10x Genomics
2.20
Hold$32.08-26.65% Downside

Current Analyst Ratings Breakdown

Latest ILMN, GRAL, TXG, PACB, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetOutperform$175.00 ➝ $210.00
7/17/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetMarket Perform$23.00 ➝ $40.00
7/15/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Reiterated RatingBuy
7/15/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Reiterated RatingHold
7/15/2026
Illumina, Inc. stock logo
ILMN
Illumina
Reiterated RatingHold
7/15/2026
10x Genomics stock logo
TXG
10x Genomics
Reiterated RatingHold
7/15/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Boost Price TargetNeutral$58.00 ➝ $65.00
7/14/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Set Price TargetBuyHold$45.50
7/14/2026
Illumina, Inc. stock logo
ILMN
Illumina
Boost Price TargetHold$140.00 ➝ $190.00
7/14/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetBuy$32.00 ➝ $50.00
7/9/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetEqual Weight$22.00 ➝ $37.00
(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M21.18N/AN/A$66.13 per share1.10
Illumina, Inc. stock logo
ILMN
Illumina
$4.34B6.50$6.59 per share28.33$17.82 per share10.47
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$160.01M2.80$0.76 per share1.89$0.02 per share72.00
Qiagen N.V. stock logo
QGEN
Qiagen
$2.09B4.06$3.38 per share12.19$17.89 per share2.30
10x Genomics stock logo
TXG
10x Genomics
$642.82M8.64N/AN/A$6.24 per share7.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$10.37N/AN/AN/A-253.22%-16.42%-14.34%8/11/2026 (Estimated)
Illumina, Inc. stock logo
ILMN
Illumina
$850M$5.5033.9431.853.5619.42%31.01%12.22%7/30/2026 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$546.38M-$0.43N/AN/AN/A-80.35%-571.06%-18.82%8/3/2026 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$424.88M$1.9121.5115.724.1419.16%14.40%8.40%8/5/2026 (Confirmed)
10x Genomics stock logo
TXG
10x Genomics
-$43.54M-$0.17N/AN/AN/A-3.55%-2.86%-2.23%8/6/2026 (Estimated)

Latest ILMN, GRAL, TXG, PACB, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.6556N/AN/AN/A$42.39 millionN/A
8/6/2026Q2 2026
10x Genomics stock logo
TXG
10x Genomics
-$0.23N/AN/AN/A$146.67 millionN/A
8/5/2026Q2 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60N/AN/AN/A$527.65 millionN/A
8/3/2026Q2 2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.1280N/AN/AN/A$42.90 millionN/A
7/30/2026Q2 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.24N/AN/AN/A$1.13 billionN/A
5/7/2026Q1 2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.17-$0.12+$0.05-$0.03$39.94 million$37.18 million
5/7/2026Q1 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.54$0.54N/A$0.33$496.15 million$492.32 million
5/7/2026Q1 2026
10x Genomics stock logo
TXG
10x Genomics
-$0.29-$0.10+$0.19-$0.10$146.41 million$150.84 million
5/5/2026Q1 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.7629-$2.29+$0.4729-$2.29$39.16 million$40.79 million
4/30/2026Q1 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.05$1.15+$0.10$0.87$1.07 billion$1.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.350.85%N/A18.32%N/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest ILMN, GRAL, TXG, PACB, and QGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/11/2026
Qiagen N.V. stock logo
QGEN
Qiagen
annual$0.350.9%7/7/20267/7/20267/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
11.74
11.74
Illumina, Inc. stock logo
ILMN
Illumina
0.56
1.75
1.36
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
5.65
4.87
Qiagen N.V. stock logo
QGEN
Qiagen
0.49
3.21
2.57
10x Genomics stock logo
TXG
10x Genomics
N/A
5.90
5.42

Institutional Ownership

CompanyInstitutional Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Illumina, Inc. stock logo
ILMN
Illumina
2.90%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
3.70%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
10x Genomics stock logo
TXG
10x Genomics
8.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36042.92 million42.13 millionOptionable
Illumina, Inc. stock logo
ILMN
Illumina
8,650151.30 million146.91 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730310.60 million299.11 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,654206.07 million187.53 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240126.96 million115.73 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAIL stock logo

GRAIL NASDAQ:GRAL

$72.62 +0.66 (+0.92%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$71.52 -1.10 (-1.51%)
As of 07/17/2026 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Illumina stock logo

Illumina NASDAQ:ILMN

$186.65 -3.60 (-1.89%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$186.71 +0.06 (+0.03%)
As of 07/17/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.44 -0.05 (-3.36%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$1.43 -0.01 (-0.42%)
As of 07/17/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$41.19 -0.32 (-0.78%)
Closing price 07/17/2026 03:59 PM Eastern
Extended Trading
$41.14 -0.05 (-0.11%)
As of 07/17/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$43.74 -0.74 (-1.66%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$43.89 +0.15 (+0.35%)
As of 07/17/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.